Individualized Metacognitive Therapy (MCT+) for patients with schizophrenia - 5 year follow-up

Not Applicable

Recruiting

• Conditions: F20-F29; Schizophrenia, schizotypal and delusional disorders

• Registration Number: DRKS00022190
• Lead Sponsor: niversitätsklinikum Hamburg-EppendorfKlinik und Poliklinik für Psychiatrie und Psychotherapie

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2020-07-09
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 329

Inclusion Criteria

This trial does not aim to recruit any new subjects, but rather to contact and reassess previously included study participants.

1) Schizophrenic spectrum disorder (ICD-F2x, verified using the MINI)
2) Ability to consent

Exclusion Criteria

1) Intelligence: IQ < 70, measured with a vocabulary test (WST)
2) Rating for uncooperative behaviour and hostility = 5 on the PANSS scale (range: 1-7; G8, P7)
3) Acute suicidality
4) Current substance and alcohol dependence, except tobacco (i.e. abstinence < 6 months; substance and alcohol abuse are tolerated)
5) neurological or medical disease that may cause the psychotic symptoms
6) Participation in MCT+ within the last 12 months
7) Insufficient knowledge of German for participation in MCT+
8) insufficient testability

Study & Design

• Study Type: interventional
• Study Design: Not specified